Clinical Trial Update: Effectiveness of GSK598809, a Selective D3 Antagonist, Added to CBT and NRT for Smoking Cessation and Relapse Prevention [Phase 2]

View source ↗

Summary

This Phase 2 trial evaluated whether adding GSK598809 to CBT and nicotine replacement therapy improves smoking cessation and relapse prevention in nicotine depe…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Nicotine Dependence

Drugs mentioned

• GSK598809 (GSK598809)

Snippet

Sponsor: Massachusetts General Hospital | Conditions: Nicotine Dependence | Phase 2 | Status: COMPLETED | Results posted: 2017-01-09